Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

SION-719’s Phase 2a proof-of-concept trial failed to achieve the key activity endpoint (sweat chloride reduction) when added to standard of care. The company will not advance SION-719 as an add-on therapy to standard of care, signaling a setback for the program’s clinical path.

Analysis

SION-719’s Phase 2a proof-of-concept trial failed to achieve the key activity endpoint (sweat chloride reduction) when added to standard of care. The company will not advance SION-719 as an add-on therapy to standard of care, signaling a setback for the program’s clinical path.